Last reviewed · How we verify
Therapeutic plasma exchange — Competitive Intelligence Brief
phase 3
Apheresis procedure / Extracorporeal therapy
Immunology / Neurology / Hematology
Small molecule
Live · refreshed every 30 min
Target snapshot
Therapeutic plasma exchange (Therapeutic plasma exchange) — Centre Hospitalier St Anne. Therapeutic plasma exchange removes pathogenic antibodies, immune complexes, and other harmful plasma constituents by separating and replacing the patient's plasma with donor plasma or albumin solution.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Therapeutic plasma exchange TARGET | Therapeutic plasma exchange | Centre Hospitalier St Anne | phase 3 | Apheresis procedure / Extracorporeal therapy |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Apheresis procedure / Extracorporeal therapy class)
- Centre Hospitalier St Anne · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Therapeutic plasma exchange CI watch — RSS
- Therapeutic plasma exchange CI watch — Atom
- Therapeutic plasma exchange CI watch — JSON
- Therapeutic plasma exchange alone — RSS
- Whole Apheresis procedure / Extracorporeal therapy class — RSS
Cite this brief
Drug Landscape (2026). Therapeutic plasma exchange — Competitive Intelligence Brief. https://druglandscape.com/ci/therapeutic-plasma-exchange. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab